Strategies for mitigating severe COVID-19 in patients with haematological malignancy during the omicron era
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkaf489 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Keiji Okinaka und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, National Cancer Center Hospital East, Chiba, Japan. Hauptthemen laut MEDLINE: Hematologic Neoplasms, COVID-19, Pandemics. Die Arbeit nennt 131 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Despite a decrease in disease severity since the emergence of the severe acute respiratory syndrome coronavirus 2 Omicron variant, coronavirus disease-2019 (COVID-19) continues to pose a significant threat to patients with haematological malignancies (HM). Although repeated booster vaccinations enhance protection against severe illnesses in immunocompromised individuals, they remain at heightened risk of adverse outcomes. This underscores the crucial need for effective pharmacologic strategies to prevent and treat infection. This review examines current strategies for preventing severe COVID-19 in patients with HM, focusing on pre-exposure prophylaxis and early treatment of COVID-19. New monoclonal antibodies have been developed, offering effective pre-exposure prophylaxis. Antiviral agents and monoclonal antibodies demonstrated efficacy in limiting severe COVID-19 outcomes in patients with HM, though some patients, particularly the elderly, remain at risk of critical illness and death. Prolonged infection over months is also common, particularly in patients with lymphoid malignancies. Sustained viral shedding and ongoing mutation may be associated with chronic symptoms and is the likely source of several novel variants of concern that prolonged the pandemic. While HM subtype and advanced age are risk factors for severe or persistent COVID-19, there are no accurate tools for predicting individual risk. Given this uncertainty, prompt medical consultation, timely prescription of antiviral agents, and close monitoring are essential to minimize the risk of adverse outcomes in this vulnerable population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, National Cancer Center Hospital East, Chiba, Japan.
- Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
- Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
- Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
- Department of Medicine, University of Washington, Seattle, WA, USA.
ORCID-Profile: Keiji Okinaka, Joshua T Schiffer
Förderung
- NIAID NIH HHS
Zitieren
APA
Okinaka, K., & Schiffer, J. T. (2026). Strategies for mitigating severe COVID-19 in patients with haematological malignancy during the omicron era. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf489
Vancouver
Okinaka K, Schiffer JT. Strategies for mitigating severe COVID-19 in patients with haematological malignancy during the omicron era. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkaf489
BibTeX
@article{Okinaka2026,
author = {Okinaka, Keiji and Schiffer, Joshua T},
title = {Strategies for mitigating severe COVID-19 in patients with haematological malignancy during the omicron era},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkaf489}
}
EUVIMED